Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Leonard B Saltz
No abstract text is available yet for this article.
March 8, 2019: Lancet Oncology
#2
REVIEW
C S Pramesh, Harit Chaturvedi, Vijay Anand Reddy, Tapan Saikia, Sushmita Ghoshal, Mrinalini Pandit, K Govind Babu, K V Ganpathy, Dhairyasheel Savant, Gunita Mitera, Richard Sullivan, Christopher M Booth
The Choosing Wisely India campaign was an initiative that was established to identify low-value or potentially harmful practices that are relevant to the Indian cancer health-care system. We undertook a multidisciplinary framework-driven consensus process to identify a list of low-value or harmful cancer practices that are frequently undertaken in India. A task force convened by the National Cancer Grid of India included Indian representatives from surgical, medical, and radiation oncology. Each specialty had representation from the private and public sectors...
March 8, 2019: Lancet Oncology
#3
Funda Meric-Bernstam, Herbert Hurwitz, Kanwal Pratap Singh Raghav, Robert R McWilliams, Marwan Fakih, Ari VanderWalde, Charles Swanton, Razelle Kurzrock, Howard Burris, Christopher Sweeney, Ron Bose, David R Spigel, Mary S Beattie, Steven Blotner, Alyssa Stone, Katja Schulze, Vaikunth Cuchelkar, John Hainsworth
BACKGROUND: Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast and gastric cancers, and are emerging as potential treatments for HER2-positive metastatic colorectal cancer. MyPathway evaluates the activity of targeted therapies in non-indicated tumour types with potentially predictive molecular alterations. We aimed to assess the activity of pertuzumab and trastuzumab in patients with HER2-amplified metastatic colorectal cancer. METHODS: MyPathway is an ongoing, phase 2a, multiple basket study...
March 8, 2019: Lancet Oncology
#4
Elizabeth Gourd
No abstract text is available yet for this article.
March 7, 2019: Lancet Oncology
#5
David A Mankoff, Amy S Clark
No abstract text is available yet for this article.
March 4, 2019: Lancet Oncology
#6
Sun Young Chae, Sei Hyun Ahn, Sung-Bae Kim, Sangwon Han, Suk Hyun Lee, Seung Jun Oh, Sang Ju Lee, Hee Jeong Kim, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Jisun Kim, Jin-Hee Ahn, Kyung Hae Jung, Jeong Eun Kim, Seog-Young Kim, Woo Jung Choi, Hee Jung Shin, Gyungyub Gong, Hyo Sang Lee, Jung Bok Lee, Dae Hyuk Moon
BACKGROUND: A biopsy of first recurrence or metastatic disease is recommended to re-evaluate oestrogen receptor status in patients with breast cancer and to select appropriate treatment. However, retesting for oestrogen receptor status with rebiopsy is not always feasible, depending on lesion location and the risk associated with biopsy, and in these cases clinicians continue to treat patients according to the oestrogen receptor status of the primary tumour. Consequently suboptimal therapy might be offered to these patients...
March 4, 2019: Lancet Oncology
#7
Robert Stirrups
No abstract text is available yet for this article.
February 28, 2019: Lancet Oncology
#8
Paul Russo
No abstract text is available yet for this article.
February 28, 2019: Lancet Oncology
#9
Nieves Martínez Chanzá, Wanling Xie, Mehmet Asim Bilen, Hannah Dzimitrowicz, Jarred Burkart, Daniel M Geynisman, Archana Balakrishnan, I Alex Bowman, Rohit Jain, Walter Stadler, Yousef Zakharia, Vivek Narayan, Benoit Beuselinck, Rana R McKay, Abhishek Tripathi, Russell Pachynski, Andrew W Hahn, JoAnn Hsu, Sumit A Shah, Elaine T Lam, Tracy L Rose, Anthony E Mega, Nicholas Vogelzang, Michael R Harrison, Amir Mortazavi, Elizabeth R Plimack, Ulka Vaishampayan, Hans Hammers, Saby George, Naomi Haas, Neeraj Agarwal, Sumanta K Pal, Sandy Srinivas, Benedito A Carneiro, Daniel Y C Heng, Dominick Bosse, Toni K Choueiri, Lauren C Harshman
BACKGROUND: Cabozantinib is approved for patients with metastatic renal cell carcinoma on the basis of studies done in clear-cell histology. The activity of cabozantinib in patients with non-clear-cell renal cell carcinoma is poorly characterised. We sought to analyse the antitumour activity and toxicity of cabozantinib in advanced non-clear-cell renal cell carcinoma. METHODS: We did a multicentre, international, retrospective cohort study of patients with metastatic non-clear-cell renal cell carcinoma treated with oral cabozantinib during any treatment line at 22 centres: 21 in the USA and one in Belgium...
February 28, 2019: Lancet Oncology
#10
Eva Steliarova-Foucher
No abstract text is available yet for this article.
February 26, 2019: Lancet Oncology
#11
Zachary J Ward, Jennifer M Yeh, Nickhill Bhakta, A Lindsay Frazier, Rifat Atun
BACKGROUND: Accurate estimates of childhood cancer incidence are important for policy makers to inform priority setting and planning decisions. However, many countries do not have cancer registries that quantify the incidence of childhood cancer. Moreover, even when registries do exist, they might substantially underestimate the true incidence, since children with cancer might not be diagnosed. We therefore aimed to provide estimates of total childhood cancer incidence accounting for underdiagnosis...
February 26, 2019: Lancet Oncology
#12
Mary Beth Terry, Yuyan Liao, Alice S Whittemore, Nicole Leoce, Richard Buchsbaum, Nur Zeinomar, Gillian S Dite, Wendy K Chung, Julia A Knight, Melissa C Southey, Roger L Milne, David Goldgar, Graham G Giles, Sue-Anne McLachlan, Michael L Friedlander, Prue C Weideman, Gord Glendon, Stephanie Nesci, Irene L Andrulis, Esther M John, Kelly-Anne Phillips, Mary B Daly, Saundra S Buys, John L Hopper, Robert J MacInnis
BACKGROUND: Independent validation is essential to justify use of models of breast cancer risk prediction and inform decisions about prevention options and screening. Few independent validations had been done using cohorts for common breast cancer risk prediction models, and those that have been done had small sample sizes and short follow-up periods, and used earlier versions of the prediction tools. We aimed to validate the relative performance of four commonly used models of breast cancer risk and assess the effect of limited data input on each one's performance...
February 21, 2019: Lancet Oncology
#13
Manjulika Das
No abstract text is available yet for this article.
February 21, 2019: Lancet Oncology
#14
Elizabeth Gourd
No abstract text is available yet for this article.
February 21, 2019: Lancet Oncology
#15
Robert Stirrups
No abstract text is available yet for this article.
February 21, 2019: Lancet Oncology
#16
Montserrat Garcia-Closas, Nilanjan Chatterjee
No abstract text is available yet for this article.
February 21, 2019: Lancet Oncology
#17
Talha Burki
No abstract text is available yet for this article.
February 21, 2019: Lancet Oncology
#18
Sumit Gupta
No abstract text is available yet for this article.
February 20, 2019: Lancet Oncology
#19
Chloe J Bright, Raoul C Reulen, David L Winter, Daniel P Stark, Martin G McCabe, Angela B Edgar, Clare Frobisher, Michael M Hawkins
BACKGROUND: Few studies have investigated the risks of subsequent primary neoplasms after adolescent and young adult (AYA) cancer. We investigated the risks of specific subsequent primary neoplasms after each of 16 types of AYA cancer. METHODS: The Teenage and Young Adult Cancer Survivor Study is a population-based cohort of 200 945 survivors of cancer diagnosed when aged 15-39 years in England and Wales from Jan 1, 1971, to Dec 31, 2006. The cohort was established using cancer registrations from the Office for National Statistics and the Welsh Cancer registry...
February 20, 2019: Lancet Oncology
#20
Marc Brisson, Mélanie Drolet
No abstract text is available yet for this article.
February 19, 2019: Lancet Oncology
Fetching more papers... 
